Cargando…

Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma

OBJECTIVE: This study aims to explore the feasibility of a hysteroscopic procedure combined with progestin therapy in young patients with stage Ia endometrioid carcinoma (EC) to avoid sterilization. MATERIALS AND METHODS: Eleven young women with stage Ia EC (International Federation of Gynecology an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fangfang, Yu, Aijun, Xu, Haichao, Zhang, Xiaojing, Li, Li, Lou, Hanmei, Yu, Hua, Lin, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671800/
https://www.ncbi.nlm.nih.gov/pubmed/28885274
http://dx.doi.org/10.1097/IGC.0000000000001109
_version_ 1783276310155493376
author Wang, Fangfang
Yu, Aijun
Xu, Haichao
Zhang, Xiaojing
Li, Li
Lou, Hanmei
Yu, Hua
Lin, Jun
author_facet Wang, Fangfang
Yu, Aijun
Xu, Haichao
Zhang, Xiaojing
Li, Li
Lou, Hanmei
Yu, Hua
Lin, Jun
author_sort Wang, Fangfang
collection PubMed
description OBJECTIVE: This study aims to explore the feasibility of a hysteroscopic procedure combined with progestin therapy in young patients with stage Ia endometrioid carcinoma (EC) to avoid sterilization. MATERIALS AND METHODS: Eleven young women with stage Ia EC (International Federation of Gynecology and Obstetrics grade 1) who were treated with a hysteroscopic approach combined with progestin from July 2004 to June 2016 were retrospectively analyzed and followed up to monitor their general recovery and pregnancy outcome. RESULTS: The patients' median age was 27.3 years (range, 25–39 years). Comorbidities consisted of primary infertility in 8 patients, polycystic ovary syndrome in 4, uterine fibroids in 2, and diabetes in 1. The results of immunohistochemical analysis were positive for all estrogen and progestin receptors. After treatment, 9 patients attained complete remission, and 2 patients achieved partial remission. The results of peritoneal cytology in 4 patients were negative. As of this writing, 6 of the 11 patients have given birth to 7 infants, and 1 patient had an ectopic pregnancy. Two patients ultimately underwent radical resection. The average follow-up time was 82.3 months (range, 15 to 152 months), and all patients remain disease-free. CONCLUSIONS: Hysteroscopic surgery combined with progestin treatment for stage Ia EC in young patients to avoid sterilization was practical and may represent a new option for patients with stage Ia EC who wish to preserve their fertility.
format Online
Article
Text
id pubmed-5671800
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-56718002017-11-22 Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma Wang, Fangfang Yu, Aijun Xu, Haichao Zhang, Xiaojing Li, Li Lou, Hanmei Yu, Hua Lin, Jun Int J Gynecol Cancer Uterine Cancer OBJECTIVE: This study aims to explore the feasibility of a hysteroscopic procedure combined with progestin therapy in young patients with stage Ia endometrioid carcinoma (EC) to avoid sterilization. MATERIALS AND METHODS: Eleven young women with stage Ia EC (International Federation of Gynecology and Obstetrics grade 1) who were treated with a hysteroscopic approach combined with progestin from July 2004 to June 2016 were retrospectively analyzed and followed up to monitor their general recovery and pregnancy outcome. RESULTS: The patients' median age was 27.3 years (range, 25–39 years). Comorbidities consisted of primary infertility in 8 patients, polycystic ovary syndrome in 4, uterine fibroids in 2, and diabetes in 1. The results of immunohistochemical analysis were positive for all estrogen and progestin receptors. After treatment, 9 patients attained complete remission, and 2 patients achieved partial remission. The results of peritoneal cytology in 4 patients were negative. As of this writing, 6 of the 11 patients have given birth to 7 infants, and 1 patient had an ectopic pregnancy. Two patients ultimately underwent radical resection. The average follow-up time was 82.3 months (range, 15 to 152 months), and all patients remain disease-free. CONCLUSIONS: Hysteroscopic surgery combined with progestin treatment for stage Ia EC in young patients to avoid sterilization was practical and may represent a new option for patients with stage Ia EC who wish to preserve their fertility. Lippincott Williams & Wilkins 2017-11 2017-08-31 /pmc/articles/PMC5671800/ /pubmed/28885274 http://dx.doi.org/10.1097/IGC.0000000000001109 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of IGCS and ESGO. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Uterine Cancer
Wang, Fangfang
Yu, Aijun
Xu, Haichao
Zhang, Xiaojing
Li, Li
Lou, Hanmei
Yu, Hua
Lin, Jun
Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma
title Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma
title_full Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma
title_fullStr Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma
title_full_unstemmed Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma
title_short Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma
title_sort fertility preserved hysteroscopic approach for the treatment of stage ia endometrioid carcinoma
topic Uterine Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671800/
https://www.ncbi.nlm.nih.gov/pubmed/28885274
http://dx.doi.org/10.1097/IGC.0000000000001109
work_keys_str_mv AT wangfangfang fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma
AT yuaijun fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma
AT xuhaichao fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma
AT zhangxiaojing fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma
AT lili fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma
AT louhanmei fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma
AT yuhua fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma
AT linjun fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma